Profile data is unavailable for this security.
About the company
Sana Biotechnology, Inc. is a biotechnology company focusing on utilizing engineered cells as medicines. It is engaged in developing cell engineering programs to revolutionize treatment across an array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune and central nervous system disorders. It develops a pipeline of clinical product candidates focused on creating transformative ex vivo therapies across a range of therapeutic areas. Its pipeline includes SC291, SC262, SC255, C379, SC451 and UP421. It is applying its hypoimmune technology to donor derived T cells to be used as allogeneic cell therapies for hematologic malignancies. It is developing SC255, a B-cell maturation antigen-directed allogeneic CAR T, for the treatment of multiple myeloma. It is developing SC262, its hypoimmune-modified CD22-directed allogeneic CAR T program, initially as a potential treatment for patients with relapsed and/or refractory B-cell malignancies.
- Revenue in USD (TTM)0.00
- Net income in USD-308.61m
- Incorporated2018
- Employees328.00
- LocationSana Biotechnology Inc188 East Blaine Street, Suite 400SEATTLE 98102United StatesUSA
- Phone+1 (206) 701-7914
- Fax+1 (302) 636-5454
- Websitehttps://sana.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Harmony Biosciences Holdings Inc | 617.51m | 137.70m | 1.68bn | 246.00 | 12.80 | 3.27 | 10.39 | 2.73 | 2.32 | 2.32 | 10.39 | 9.08 | 0.7906 | 25.72 | 9.34 | 2,510,207.00 | 17.63 | 7.46 | 20.83 | 9.08 | 79.28 | 80.58 | 22.30 | 10.46 | 3.07 | 31.38 | 0.2694 | 0.00 | 32.93 | -- | -28.99 | -- | -25.31 | -- |
| Kura Oncology Inc | 0.00 | -168.09m | 1.68bn | 142.00 | -- | 3.33 | -- | -- | -2.18 | -2.18 | 0.00 | 6.63 | 0.00 | -- | -- | 0.00 | -34.31 | -26.04 | -36.21 | -27.45 | -- | -- | -- | -- | -- | -- | 0.0182 | -- | -- | -- | -12.36 | -- | -- | -- |
| Syndax Pharmaceuticals Inc | 0.00 | -240.63m | 1.76bn | 112.00 | -- | 3.57 | -- | -- | -3.22 | -3.22 | 0.00 | 5.79 | 0.00 | -- | -- | 0.00 | -47.99 | -27.90 | -51.84 | -30.15 | -- | -- | -- | -324.34 | -- | -- | 0.00004 | -- | -- | -- | -40.19 | -- | -- | -- |
| Inhibrx Inc | 1.78m | -271.16m | 1.79bn | 166.00 | -- | 145.73 | -- | 1,006.31 | -5.35 | -5.35 | 0.0358 | 0.235 | 0.0066 | -- | 7.51 | 10,740.96 | -99.40 | -77.06 | -123.13 | -93.91 | -- | -- | -15,116.15 | -1,590.91 | -- | -12.67 | 0.9474 | -- | -17.88 | -26.85 | -66.20 | -- | 26.30 | -- |
| Ardelyx Inc | 159.11m | -65.81m | 1.81bn | 267.00 | -- | 11.97 | -- | 11.35 | -0.2883 | -0.2883 | 0.7007 | 0.6449 | 0.5689 | 3.20 | 7.90 | 595,917.60 | -23.53 | -46.14 | -29.95 | -57.32 | 85.30 | 88.15 | -41.36 | -240.87 | 4.36 | -9.86 | 0.3982 | -- | 138.61 | 116.66 | 1.70 | -- | 2.04 | -- |
| Keros Therapeutics Inc | 234.00k | -160.30m | 1.82bn | 141.00 | -- | 4.01 | -- | 7,776.54 | -5.14 | -5.14 | 0.0075 | 12.59 | 0.0005 | -- | -- | 1,720.59 | -36.84 | -35.95 | -38.35 | -38.07 | -- | -- | -68,505.13 | -1,237.26 | -- | -- | 0.00 | -- | -- | -56.77 | -46.15 | -- | 62.57 | -- |
| Fusion Pharmaceuticals Inc | 2.04m | -104.28m | 1.83bn | 113.00 | -- | 7.54 | -- | 896.05 | -1.42 | -1.42 | 0.0279 | 2.85 | 0.0069 | -- | 45.84 | 18,053.10 | -35.33 | -35.45 | -37.76 | -38.55 | -- | -- | -5,111.57 | -7,206.24 | -- | -- | 0.1704 | -- | 41.55 | -- | -8.32 | -- | 28.21 | -- |
| Sana Biotechnology Inc | 0.00 | -308.61m | 1.84bn | 328.00 | -- | 4.90 | -- | -- | -1.53 | -1.53 | 0.00 | 1.70 | 0.00 | -- | -- | 0.00 | -43.21 | -38.99 | -48.50 | -42.70 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.11 | -- | 112.71 | -- |
| Protagonist Therapeutics Inc | 314.95m | 162.11m | 1.86bn | 124.00 | 12.90 | 3.32 | 11.40 | 5.91 | 2.46 | 2.46 | 5.25 | 9.56 | 0.7248 | -- | 2.10 | 2,812,080.00 | 37.30 | -35.90 | 40.23 | -41.36 | -- | -- | 51.47 | -332.81 | -- | -- | 0.00 | -- | 125.73 | 14.17 | 38.02 | -- | 4.62 | -- |
| Agios Pharmaceuticals Inc | 29.40m | -352.62m | 1.92bn | 383.00 | -- | 2.58 | -- | 65.42 | -6.31 | -6.31 | 0.5257 | 13.11 | 0.0294 | 0.1715 | 11.24 | 76,770.23 | -35.24 | -29.54 | -37.04 | -31.88 | 89.95 | -- | -1,199.26 | -3,826.10 | 12.39 | -- | 0.00 | -- | 88.36 | -22.25 | -51.89 | -- | -32.23 | -- |
| CG Oncology Inc | 539.00k | -72.33m | 1.93bn | 61.00 | -- | 3.39 | -- | 3,581.75 | -1.13 | -1.13 | 0.0084 | 8.54 | -- | -- | -- | 8,836.07 | -- | -- | -- | -- | -- | -- | -10,551.39 | -- | -- | -- | 0.00 | -- | 6.81 | -- | -54.83 | -- | -- | -- |
| Catalyst Pharmaceuticals Inc | 411.35m | 65.12m | 1.95bn | 167.00 | 30.70 | 3.48 | 19.36 | 4.75 | 0.5384 | 0.5384 | 3.60 | 4.76 | 0.7806 | 3.60 | 8.76 | 2,463,156.00 | 12.36 | 25.42 | 14.19 | 29.81 | 86.74 | 85.63 | 15.83 | 30.87 | 4.83 | -- | 0.00 | 0.00 | 85.90 | 280.39 | -14.05 | -- | 20.21 | -- |
Data as of May 22 2024. Currency figures normalised to Sana Biotechnology Inc's reporting currency: US Dollar USD
36.85%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 17.21m | 7.81% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 11.98m | 5.43% |
| Baillie Gifford & Co.as of 31 Mar 2024 | 10.66m | 4.83% |
| Canada Pension Plan Investment Boardas of 31 Mar 2024 | 10.18m | 4.62% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 7.60m | 3.45% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 6.37m | 2.89% |
| Capital Research & Management Co. (World Investors)as of 31 Mar 2024 | 5.45m | 2.47% |
| T. Rowe Price Investment Management, Inc.as of 31 Mar 2024 | 4.80m | 2.18% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2024 | 3.62m | 1.64% |
| Crestline Management LPas of 31 Mar 2024 | 3.37m | 1.53% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
